Journal article
Association of clinical and demographic factors with the severity of Palmoplantar Pustulosis
JAMA Dermatology, (Online First), Art. e203275
2020
Abstract
Importance Although palmoplantar pustulosis (PPP) can significantly impact quality of life, the factors underlying disease severity have not been studied.
Objective To examine the factors associated with PPP severity.
Design, Setting, and Participants An observational, cross-sectional study of 2 cohorts was conducted. A UK data set including 203 patients was obtained through the Anakinra in Pustular Psoriasis, Response in a Controlled Trial (2016-2019) and its sister research study Pustular Psoriasis, Elucidating Underlying Mechanisms (2016-2020). A Northern European cohort including 193 patients was independently ascertained by the European Rare and Severe Psoriasis Expert Network (2014-2017). Patients had been recruited in secondary or tertiary dermatology referral centers. All patients were of European descent. The PPP diagnosis was established by dermatologists, based on clinical examination and/or published consensus criteria. The present study was conducted from October 1, 2014, to March 15, 2020.
Main Outcomes and Measures Demographic characteristics, comorbidities, smoking status, Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI), measuring severity from 0 (no sign of disease) to 72 (very severe disease), or Physician Global Assessment (PGA), measuring severity as 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe).
Results Among the 203 UK patients (43 men [21%], 160 women [79%]; median age at onset, 48 [interquartile range (IQR), 38-59] years), the PPPASI was inversely correlated with age of onset (r = −0.18, P = .01). Similarly, in the 159 Northern European patients who were eligible for inclusion in this analysis (25 men [16%], 134 women [84%]; median age at onset, 45 [IQR, 34-53.3] years), the median age at onset was lower in individuals with a moderate to severe PGA score (41 years [IQR, 30.5-52 years]) compared with those with a clear to mild PGA score (46.5 years [IQR, 35-55 years]) (P = .04). In the UK sample, the median PPPASI score was higher in women (9.6 [IQR, 3.0-16.2]) vs men (4.0 [IQR, 1.0-11.7]) (P = .01). Likewise, moderate to severe PPP was more prevalent among Northern European women (57 of 134 [43%]) compared with men (5 of 25 [20%]) (P = .03). In the UK cohort, the median PPPASI score was increased in current smokers (10.7 [IQR, 4.2-17.5]) compared with former smokers (7 [IQR, 2.0-14.4]) and nonsmokers (2.2 [IQR, 1-6]) (P = .003). Comparable differences were observed in the Northern European data set, as the prevalence of moderate to severe PPP was higher in former and current smokers (51 of 130 [39%]) compared with nonsmokers (6 of 24 [25%]) (P = .14).
Conclusions and Relevance The findings of this study suggest that PPP severity is associated with early-onset disease, female sex, and smoking status. Thus, smoking cessation intervention might be beneficial.
Details
- Title
- Association of clinical and demographic factors with the severity of Palmoplantar Pustulosis
- Authors/Creators
- N. Benzian-Olsson (Author/Creator) - King's College LondonN. Dand (Author/Creator) - King's College LondonC. Chaloner (Author/Creator) - King's College LondonZ. Bata-Csorgo (Author/Creator) - University of SzegedR. Borroni (Author/Creator) - Humanitas UniversityA.D. Burden (Author/Creator) - University of GlasgowH.L. Cooper (Author/Creator) - Portsmouth Hospitals NHS TrustV. Cornelius (Author/Creator) - Imperial College LondonS. Cro (Author/Creator) - Imperial College LondonT. Dasandi (Author/Creator) - King's College LondonC.E.M. Griffiths (Author/Creator) - NIHR Manchester Biomedical Research CentreK. Kingo (Author/Creator) - Tartu University HospitalS. Kõks (Author/Creator) - Murdoch UniversityH. Lachmann (Author/Creator) - University College LondonH. McAteer (Author/Creator) - Psoriasis AssociationF. Meynell (Author/Creator) - King's College LondonU. Mrowietz (Author/Creator) - Psoriasis‐Center at the Department of Dermatology University Medical Center Schleswig‐Holstein, Campus Kiel Kiel GermanyR. Parslew (Author/Creator) - Department of Dermatology, Royal Liverpool Hospitals, Liverpool, United Kingdom.P. Patel (Author/Creator) - King's College LondonA.E. Pink (Author/Creator) - King's College LondonN.J. Reynolds (Author/Creator) - NIHR Newcastle Biomedical Research CentreA. Tanew (Author/Creator) - Medical University of ViennaK. Torz (Author/Creator) - Psoriasis‐Center at the Department of Dermatology University Medical Center Schleswig‐Holstein, Campus Kiel Kiel GermanyH. Trattner (Author/Creator) - Medical University of ViennaS. Wahie (Author/Creator) - University Hospital of North DurhamR.B. Warren (Author/Creator) - Manchester Academic Health Science CentreA. Wright (Author/Creator) - St Lukes Episcopal HospitalJ.N. Barker (Author/Creator) - King's College LondonA.A. Navarini (Author/Creator) - University Hospital of BaselC.H. Smith (Author/Creator) - King's College LondonF. Capon (Author/Creator) - King's College London
- Publication Details
- JAMA Dermatology, (Online First), Art. e203275
- Publisher
- JAMA Network
- Identifiers
- 991005542599907891
- Copyright
- © 2020 Benzian-Olsson N et al.
- Murdoch Affiliation
- Centre for Molecular Medicine and Innovative Therapeutics
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Metrics
99 File views/ downloads
38 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.106 Rheumatology
- 1.106.737 Psoriasis
- Web Of Science research areas
- Dermatology
- ESI research areas
- Clinical Medicine